secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093884
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q2 net income $0.5M, revenue $13.9M; Ono itolizumab option decision by Oct 2024
--------------------------------------------------------------------------------

- Net income $0.5M ($0.01 EPS) vs net loss $3.3M in Q2 2023; revenue $13.9M (all from Ono collaboration), up from $9.1M.
- Cash $33.3M, up $1.0M from Q1 2024; expects to fund operations for at least 12 months, adjusting spending if needed.
- Ono option to acquire itolizumab rights decision by Oct 2024; if exercised, Equillium receives JPY 5B (~$35M) plus up to $101.4M milestones.
- Phase 3 EQUATOR study (aGVHD) IDMC recommends proceed after positive interim review; no safety or futility concerns.
- Positive topline data from Phase 1b EQUALISE (lupus nephritis) and Phase 2 EQ101 (alopecia areata); preparing Phase 2b study in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000095017024093884/0000950170-24-093884-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000095017024093884/eq-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093884

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer